Pedro Berraondo

9.6k citations

164 papers · 5.9k indexed · 4 hit papers · h-index 36

Impact in

Immunology top 0.5%
- Immunotherapy and Immune Responses
- Immune Cell Function and Interaction
- Immune cells in cancer
- T-cell and B-cell Immunology
Oncology top 0.5%
- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research

Papers in

Immunology 98
- Immunotherapy and Immune Responses 63
- Immune Cell Function and Interaction 45
- Immune cells in cancer 16
- T-cell and B-cell Immunology 13
Oncology 79
- CAR-T cell therapy research 45
- Cancer Immunotherapy and Biomarkers 40

Co-authors: Ignacio Melero María C. Ochoa Miguel F. Sanmamed José Luis Perez‐Gracia María E. Rodríguez-Ruiz Iñaki Etxeberría Jesús Prìeto Mariano Ponz‐Sarvisé
Journals: OncoImmunology (13 papers)Frontiers in Immunology (8 papers)Cancer Research (8 papers)Journal for ImmunoTherapy of Cancer (8 papers)Journal of Hepatology (6 papers)
Partner nations: Spain United States United Kingdom

In The Last Decade

Pedro Berraondo

162 papers receiving 5.8k citations

Hit Papers

align trajectories log scale

Cross-priming in cancer immunology and immunotherapy 2025 · 33 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2025 Nature reviews. Cancer
2019 Nature Medicine
2019 Nature
2018 British Journal of Cancer

Peers

Countries citing papers authored by Pedro Berraondo

Since Specialization

Citations

This map shows the geographic impact of Pedro Berraondo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Pedro Berraondo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Pedro Berraondo more than expected).

Fields of papers citing papers by Pedro Berraondo

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Pedro Berraondo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Pedro Berraondo. The network helps show where Pedro Berraondo may publish in the future.

Co-authors

The 25 scholars most cited alongside Pedro Berraondo, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Pedro Berraondo Line = papers co-authored together Pedro Berraondo links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Tumor slice culture system for ex vivo immunotherapy studies Methods in cell biology ·J ANDRADE, Courtney Vaive, Virginia Belsúe, Pedro Berraondo, Ignacio Melero, Fernando Aranda	2024	1
2	Preclinical evaluation of two phylogenetically distant arenavirus vectors for the development of novel immunotherapeutic combination strategies for cancer treatment Journal for ImmunoTherapy of Cancer ·Yang XianJin, Catarina Pinto, Eriona Petro Genada Sinani, Mohamed Habbeddine, Sandra Rosskopf, Judith Strauß, 王宗元, Sarah Schmidt, Nichloas P.J. Day, P. Khulová, Karel Složil, Ethan L. Stewart, Jakub Jeż, Pedro Berraondo, Klaus K. Orlinger, Henning Lauterbach	2024	4
3	MHC class I and II-deficient humanized mice are suitable tools to test the long-term antitumor efficacy of immune checkpoint inhibitors and T-cell engagers Journal for ImmunoTherapy of Cancer ·Iñaki Eguren‐Santamaría, Hassan Malli, Natalya Zoe Weinstein, Albert Verwilghen, Marı́a G. Campos, JunHyun Lee, 智徳下西, 中西祐太, Rafael Salido‐Vallejo, Dagnachew Aklog Yihun, Carlos E. de Andrea, T.B. Arulsanthosh, Pedro Berraondo, Ignacio Melero, Miguel F. Sanmamed	2024	4
4	Intraperitoneal administration of a modified vaccinia virus Ankara confers single-chain interleukin-12 expression to the omentum and achieves immune-mediated efficacy against peritoneal carcinomatosis Journal for ImmunoTherapy of Cancer ·CObula Reddy, J ANDRADE, Kimiko Matsui, Mst. Tasnia Tabassum Kasfia, Candraśekhara Śāstri, Courtney Vaive, Irene Olivera, Assunta Cirella, Myriam Fernández-Sendin, Maite Álvarez, Álvaro Teijeira, Çiğdem Atay, José Medina‐Echeverz, Maria Hinterberger, Hubertus Hochrein, Ignacio Melero, Pedro Berraondo, Fernando Aranda	2023	8
5	mRNAs encoding IL-12 and a decoy-resistant variant of IL-18 synergize to engineer T cells for efficacious intratumoral adoptive immunotherapy Cell Reports Medicine ·Irene Olivera, Elixabet Bolaños, Mst. Tasnia Tabassum Kasfia, Sandra Hervás‐Stubbs, Karina V. Mariño, Carlos Luri‐Rey, Iñaki Etxeberría, Assunta Cirella, Josune Egea, Javier Glez‐Vaz, Saray Garasa, Maite Álvarez, Iñaki Eguren‐Santamaría, Sònia Guedan, Miguel F. Sanmamed, Pedro Berraondo, Gabriel A. Rabinovich, Álvaro Teijeira, Ignacio Melero	2023	32
6	Intratumoral neoadjuvant immunotherapy based on the BO-112 viral RNA mimetic OncoImmunology ·Maite Álvarez, Carmen Molina, Saray Garasa, María C. Ochoa, María E. Rodríguez-Ruiz, Ashfa Slater, Assunta Cirella, Irene Olivera, Javier Glez‐Vaz, Mst. Tasnia Tabassum Kasfia, Carlos Luri‐Rey, Arantza Azpilikueta, Elixabet Bolaños, Álvaro Teijeira, Pedro Berraondo, Marisol Quintero, Ignacio Melero	2023	10
7	Recent Insights into the Pathogenesis of Acute Porphyria Attacks and Increasing Hepatic PBGD as an Etiological Treatment Life ·A. Arias, Rosario Sánchez Martínez y José Rubio Gálvez, Ana Sampedro, Lei Jiang, Gilles Joucla, Adela Uganwa Ikwut- Ukwa, José L. Lanciego, Paolo G.V. Martini, Pedro Berraondo, Matías A. Ávila, Antonio Fontanellas	2022	12
8	Charting roadmaps towards novel and safe synergistic immunotherapy combinations Nature Cancer ·Miguel F. Sanmamed, Pedro Berraondo, María E. Rodríguez-Ruiz, Ignacio Melero	2022	25
9	Intracavitary adoptive transfer of IL-12 mRNA-engineered tumor-specific CD8 ⁺ T cells eradicates peritoneal metastases in mouse models OncoImmunology ·Kimiko Matsui, Assunta Cirella, J ANDRADE, CObula Reddy, Myriam Fernández-Sendin, Courtney Vaive, Candraśekhara Śāstri, Irene Olivera, R. Gladyshevskii, Mst. Tasnia Tabassum Kasfia, Maite Álvarez, Iñaki Etxeberría, Belén Palencia, Álvaro Teijeira, Ignacio Melero, Pedro Berraondo, Fernando Aranda	2022	9
10	Anti-TGFβ (Transforming Growth Factor β) Therapy With Betaglycan-Derived P144 Peptide Gene Delivery Prevents the Formation of Aortic Aneurysm in a Mouse Model of Marfan Syndrome Arteriosclerosis Thrombosis and Vascular Biology ·Cristina Arce, 横山典子, 爽罗, J LeBouton, Victoria Campuzano, Isabel Fabregat, Francesc Jiménez‐Altayó, Pedro Berraondo, Gustavo Egea	2021	16
11	Immunotherapy Moves to the Early-Stage Setting in Non-Small Cell Lung Cancer: Emerging Evidence and the Role of Biomarkers Cancers ·Xabier Mielgo-Rubio, Virginia Calvo, J. Luna, Jordi Remón, M. Martín, Pedro Berraondo, J.R. Jarabo, Oliver Higuera, Esther Conde, Javier de Castro, Mariano Provencio, Florentino Hernándo, Fernando López‐Ríos, Felipe Couñago	2020	9
12	Treatment of Experimental Autoimmune Encephalomyelitis by Sustained Delivery of Low-Dose IFN-α The Journal of Immunology ·Marcos Vásquez, Marta Consuegra‐Fernández, Fernando Aranda, А Ш Шакен, Muthukumaran Jagannatham, Myriam Fernández-Sendin, Candraśekhara Śāstri, 和弘古川, Kimiko Matsui, Noëlia Casares, Juan José Lasarte, Francisco Lozano, Pedro Berraondo	2019	7
13	TGFβ Blockade Enhances Radiotherapy Abscopal Efficacy Effects in Combination with Anti-PD1 and Anti-CD137 Immunostimulatory Monoclonal Antibodies Molecular Cancer Therapeutics ·María E. Rodríguez-Ruiz, Inmaculada Rodríguez, O.E.V. Dingemans, Tania Labiano, Benigno Barbés, Iñaki Etxeberría, Mariano Ponz‐Sarvisé, Arantza Azpilikueta, Elixabet Bolaños, Miguel F. Sanmamed, Pedro Berraondo, Felipe A. Calvo, Mary Helen Barcellos‐Hoff, José Luis Perez‐Gracia, Ignacio Melero	2019	71
14	Intratumoral Immunotherapy with XCL1 and sFlt3L Encoded in Recombinant Semliki Forest Virus–Derived Vectors Fosters Dendritic Cell–Mediated T-cell Cross-Priming Cancer Research ·Alfonso R. Sánchez-Paulete, Álvaro Teijeira, José I. Quetglas, María E. Rodríguez-Ruiz, Álvaro Sánchez-Arráez, Sara Labiano, Iñaki Etxeberría, Arantza Azpilikueta, Elixabet Bolaños, 敏彦藤本, Noëlia Casares, Sergio A. Quezada, Pedro Berraondo, David Sancho, Cristian Smerdou, Ignacio Melero	2018	69
15	Tumor-Produced Interleukin-8 Attracts Human Myeloid-Derived Suppressor Cells and Elicits Extrusion of Neutrophil Extracellular Traps (NETs) Clinical Cancer Research ·Carlos Alfaro, Álvaro Teijeira, Carmen Oñate, Guiomar Pérez, Miguel F. Sanmamed, Maria Pilar Andueza, Diego Alignani, Sara Labiano, Arantza Azpilikueta, Alfonso Rodriguez-Paulete, Saray Garasa, Juan P. Fusco, Ángela Aznar, Susana Inogés, Maria De Pizzol, Marcello Allegretti, José Medina‐Echeverz, Pedro Berraondo, José Luis Perez‐Gracia, Ignacio Melero	2016	316
16	Immunostimulatory Monoclonal Antibodies and Immunomodulation: Harvesting the Crop Cancer Research ·Pedro Berraondo, María C. Ochoa, María E. Rodríguez-Ruiz, Luna Minute, Juan José Lasarte, Ignacio Melero	2016	3
17	Antitumor Immunotherapeutic and Toxic Properties of an HDL-Conjugated Chimeric IL-15 Fusion Protein Cancer Research ·María C. Ochoa, Jessica Fioravanti, Inmaculada Rodríguez, Sandra Hervás‐Stubbs, Arantza Azpilikueta, Guillermo Mazzolini, Alfonso Gúrpide, Jesús Prìeto, Julián Pardo, Pedro Berraondo, Ignacio Melero	2012	39
18	Changing the Tumor Microenvironment: New Strategies for Immunotherapy Cancer Research ·Pedro Berraondo, Viktor Umansky, Ignacio Melero	2012	21
19	Eradication of Large Tumors in Mice by a Tritherapy Targeting the Innate, Adaptive, and Regulatory Components of the Immune System Cancer Research ·Pedro Berraondo, Xiaona Hou, Xavier Préville, Daniel Ladant, Claude Leclerc	2007	88
20	Low Surface Expression of B7-1 (CD80) Is an Immunoescape Mechanism of Colon Carcinoma Cancer Research ·Iñigo Tirapu, Eduardo Huarte, Cristiana Guiducci, Ainhoa Arina, Mikel Zaratiegui, Oihana Murillo, Álvaro González, Carmen Berasain, Pedro Berraondo, Puri Fortes, Jesús Prìeto, Mario P. Colombo, Lieping Chen, Ignacio Melero	2006	116

About Pedro Berraondo

Pedro Berraondo is a scholar working on Immunology, Oncology, Hepatology, Genetics and Animal Science and Zoology, having authored 164 papers that have together received 5.9k indexed citations. Recurring topics across this work include Immunotherapy and Immune Responses (63 papers), CAR-T cell therapy research (45 papers), Immune Cell Function and Interaction (45 papers), Cancer Immunotherapy and Biomarkers (40 papers), Virus-based gene therapy research (30 papers), Immune cells in cancer (16 papers), T-cell and B-cell Immunology (13 papers) and RNA Interference and Gene Delivery (11 papers). The work is most often cited by research in Immunology (3.3k citations), Oncology (2.9k citations), Genetics (370 citations), Genetics (747 citations) and Molecular Biology (1.8k citations). Pedro Berraondo has collaborated with scholars based in Spain, United States and United Kingdom. Frequent co-authors include Ignacio Melero, María C. Ochoa, Miguel F. Sanmamed, José Luis Perez‐Gracia, María E. Rodríguez-Ruiz, Iñaki Etxeberría, Jesús Prìeto, Mariano Ponz‐Sarvisé, Álvaro Teijeira and Eduardo Castañón. Their work appears in journals such as OncoImmunology, Frontiers in Immunology, Cancer Research, Journal for ImmunoTherapy of Cancer and Journal of Hepatology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact